Survey of attitudes of mental health professionals in Singapore towards at-risk mental states

Singapore Medical Journal

Volumn 49, Issue 1, 2008, Pages 37-41

  Tor, Phern Chern ^a   Poon, L Y ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

At risk mental states; Chronic mental illness; Clinical equipoise; Psychosis; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CONSENSUS; CONTROLLED STUDY; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; MENTAL HEALTH CARE; PSYCHIATRIST; PSYCHOSIS; RISK ASSESSMENT; SINGAPORE; VIGNETTE;

ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PREVALENCE; PSYCHIATRY; QUESTIONNAIRES; SCHIZOPHRENIA; SINGAPORE;

EID: 39049156278     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Murray CJL, Lopez AD, eds. The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard University Press, 1996.
2. Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149:1183-8.
3. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. Am J Psychiatry 1993; 150:1349-54.
4. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998; 172:14-20.
5. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:790-9.
6. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-8.
7. McGorry PD. Preventive strategies in early psychosis: verging on reality. Br J Psychiatry Suppl 1998; 172:1-2.
8. Melle I, Johannesen JO, Friis S, et al. Early detection of the first episode of schizophrenia and suicidal behaviour. Am J Psychiatry 2006; 163:800-4.
9. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50:884-97.
10. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: assessment instruments. Acta Psychiatr Scand 2006; 113:273-82.
11. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand 2006; 113:247-72.
12. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51:31-8.
13. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res 2001; 51:47-54.
14. Chong SA, Lee C, Bird L, Verma S. A risk reduction approach for schizophrenia: the Early Psychosis Intervention Programme. Ann Acad Med Singapore 2004; 33:630-5.
15. White T, Anjum A, Schulz SC. The schizophrenia prodrome. Am J Psychiatry 2006; 163:376-80.
16. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-23.
17. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-64.
18. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079-87.
19. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medication. Am J Psychiatry 2006; 163:1821-5.
20. Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res 2001; 51:55-61.
21. Zubin J, Spring B. Vulnerability - a new view of schizophrenia. J Abnorm Psychol 1977; 86:103-26.
22. Lee C, McGlashan TH, Woods SW. Prevention of schizophrenia: can it be achieved? CNS Drugs 2005; 19:193-206.
23. Craig TK, Garety P, Power P, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 2004; 329:1067.
24. World Health Organization. Schizophrenia: An International Follow-up Study. New York: Wiley, 1979.
25. Thornicroft G. Shunned: Discrimination against People with Mental Illness. Oxford: Oxford University Press, 2006.
26. Block JJ. Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:1838.